Cargando…

Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease

BACKGROUND: Deep remission (DR) is a treatment target in IBD associated with reduced hospitalization and improved outcome. Randomized control trial (RCT) data demonstrates efficacy of anti-TNFα agents in achieving DR; however, real-world data (RWD) can provide information complementary to RCTs, spec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alipour, Omeed, Gualti, Alakh, Shao, Ling, Zhang, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335971/ https://www.ncbi.nlm.nih.gov/pubmed/34344314 http://dx.doi.org/10.1186/s12876-021-01883-6

Ejemplares similares

Using multiple imputation of real-world data to estimate clinical remission in pediatric inflammatory bowel disease
por: Zhang, Nanhua, et al.
Publicado: (2023)

Identification of functional missense single-nucleotide polymorphisms in TNFAIP3 in a predominantly Hispanic population
por: Zhang, Bing, et al.
Publicado: (2019)

Inflammatory Bowel Disease: How Effective Is TNF-α Suppression?
por: Lo, Wing-Cheong, et al.
Publicado: (2016)

Improving Clinical Remission Rates in Pediatric Inflammatory Bowel Disease with Previsit Planning
por: Savarino, Jeffrey R., et al.
Publicado: (2016)

Correction: Inflammatory Bowel Disease: How Effective Is TNF-α Suppression?
Publicado: (2017)

Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease
por: Amini Kadijani, Azade, et al.
Publicado: (2017)

A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma
por: Oishi, Keiji, et al.
Publicado: (2023)

Erratum: Transmembrane TNF-α Density, But Not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease
por: Amini Kadijani, Azade, et al.
Publicado: (2017)

Care of inflammatory bowel disease patients in remission
por: Raghu Subramanian, Charumathi, et al.
Publicado: (2016)

Heart Rate Recovery Is Impaired in Inflammatory Bowel Disease: Active Disease versus Remission
por: Efe, Tolga Han, et al.
Publicado: (2017)

Long-term remission and biologic persistence rates: 12-year real-world data
por: Murray, Kieran, et al.
Publicado: (2021)

An Examination of Diet for the Maintenance of Remission in Inflammatory Bowel Disease
por: Haskey, Natasha, et al.
Publicado: (2017)

A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy
por: Chebli, Júlio Maria Fonseca, et al.
Publicado: (2014)

IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
por: Strobel, Thomas, et al.
Publicado: (2020)

Anti-TNF Withdrawal in Inflammatory Bowel Disease
por: Torres, Joana, et al.
Publicado: (2016)

Polymorphisms in PRKCDBP, a Transcriptional Target of TNF-α, Are Associated With Inflammatory Bowel Disease in Korean
por: Kim, Jung-Wook, et al.
Publicado: (2015)

Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease
por: Schneider, Anna-Maria, et al.
Publicado: (2018)

Anti-TNF-α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease
por: Zhang, Cui, et al.
Publicado: (2018)

Inflammatory Bowel Disease as a Paradoxical Reaction to Anti-TNF-α Treatment—A Review
por: Mihai, Ioana Ruxandra, et al.
Publicado: (2023)

Facing Real-World Challenges of Immunogenicity in Pediatric Inflammatory Bowel Disease
por: Gress, Kyle, et al.
Publicado: (2020)

Serum biomarkers confirming stable remission in inflammatory bowel disease
por: Kessel, Christoph, et al.
Publicado: (2021)

Impact of an exercise program in children with inflammatory bowel disease in remission
por: Trivić, Ivana, et al.
Publicado: (2022)

Increased monocyte abundance as a marker for relapse after discontinuation of biologics in inflammatory bowel disease with deep remission
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Radioimmune Imaging of α(4)β(7) Integrin and TNFα for Diagnostic and Therapeutic Applications in Inflammatory Bowel Disease
por: Signore, Alberto, et al.
Publicado: (2023)

TNFα blockade prevents the development of inflammatory bowel disease in HLA-B27 transgenic rats
por: Milia, Anna Franca, et al.
Publicado: (2009)

Association of TNF-α -857 Polymorphism with Inflammatory Bowel Disease in a Group of Iranian Azeri Individuals
por: Rahbar Kafshboran, Haniyeh, et al.
Publicado: (2014)

Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study
por: Marin-Jimenez, Ignacio, et al.
Publicado: (2020)

Toward Point-of-Care Diagnostics to Monitor MMP-9 and TNF-α Levels in Inflammatory Bowel Disease
por: Liu, Dandan, et al.
Publicado: (2021)

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
por: Park, Jihye, et al.
Publicado: (2022)

Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease
por: Schultheiss, Johannes P. D., et al.
Publicado: (2021)

Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study
por: Blesl, Andreas, et al.
Publicado: (2021)

Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
por: Lie, Mitchell R. K. L., et al.
Publicado: (2018)

Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment
por: Actis, Giovanni C, et al.
Publicado: (2017)

Iron Deficiency Is Common During Remission in Children With Inflammatory Bowel Disease
por: Wikholm, Emma, et al.
Publicado: (2016)

Can vitamin D induce remission in patients with inflammatory bowel disease?
por: Goulart, Ricardo de Alvares, et al.
Publicado: (2022)

Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission
por: Pisani, Anthea, et al.
Publicado: (2022)

Rate and Predictors of Mucosal Healing in Patients with Inflammatory Bowel Disease Treated with Anti-TNF-Alpha Antibodies
por: Beigel, Florian, et al.
Publicado: (2014)

Current Nutritional Therapies in Inflammatory Bowel Disease: Improving Clinical Remission Rates and Sustainability of Long-Term Dietary Therapies
por: Reznikov, Elizabeth A., et al.
Publicado: (2023)

An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety
por: Yoshida, Kazuki, et al.
Publicado: (2011)

FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNFα Agents
por: Guidi, Luisa, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qnt3lker4l268p52crb8535m85